UNIVERSITAS GADJAH MADA
FIBROBLAST GROWTH FACTOR 23 SEBAGAI PENANDA KEJADIAN HIPERTROFI DAN DISFUNGSI VENTRIKEL KIRI PADA
PASIEN ANAK DENGAN CHRONIC KIDNEY DISEASE
YULI PRIHASTUTI, Prof.dr.Madarina Julia, MPH, Sp.A(K).; dr. Noormanto, Sp.A (K)
Universitas Gadjah Mada, 2019 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Agoro R, Montagna A, Goetz R, Aligbe O, Singh G, Coe LM, *et al*. 2018. Inhibition of fibroblast growth factor 23 signaling rescues renal anemia. *FASEB J*, 32(7): 3752–3764.

Armstrong CA, Gidding S, Gjesdal O, Wu C, Bluemke AD. 2012. LVM assessed by echocardiography and cardiac magnetic resonance, cardiovascular outcomes, and medical practice. *JACC Cardiovasc Imaging*, 5(8): 837–848.

Atalay S, Ekim M, Ercan TH, Koçak G, Bakkalŏglu S, Tümer N. 2002. Systolic and diastolic function in children with chronic renal failure. *Pediatr Int*, 44(1): 18–23.

Bergwitz C, Jüppner H. 2010. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. *Annu Rev Med*, 61: 91–104.

Bernheim J, Benchetrit S. 2011. The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. *Nephrol Dial Transplant*, 26(8): 2433–2438.

Cano FJ, Freundlich M, Ceballos ML, Rojo AP, Azocar MA, Delgado IO, *et al*.. 2014. Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis. *Clin Kidney J*, 7(5): 457–63.

Chathoth S, Al-Mueilo S, Cyrus C, Vatte C, Al-Nafaie A, Al-Ali R, *et al*. 2015. Elevated fibroblast growth factor 23 concentration: prediction of mortality among chronic kidney disease patients. *Cardiorenal Med*, 6(1): 73–82.

Chinali M, de Simone G, Matteucci MC, Picca S, Mastrostefano A, Anarat A, *et al*. 2007. Reduced systolic myocardial function in children with chronic renal insufficiency. *J Am Soc Nephrol*, 18(2): 593–598.

Collins AJ, Foley RN, Gilbertson DT, Chen SC. 2015. United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease. *Kidney Inter Suppl*, 5(1): 2–7.

Curtis BM, Parfrey PS. 2005. Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management. *Cardiol Clin*, 23(3): 275–284.

Dogan CS, Akman S, Simsek A, Ozdem S, Comak E, Gokceoglu AU, *et al*. 2015. Assessment of left ventricular function by tissue doppler echocardiography in pediatric chronic kidney disease. *Ren Fail*, 37(7): 1294–1299.

Ezumba I, Quarles LD, Kovesdy CP. 2014. FGF23 and the heart. *Giornale Italiano di Nefrologia*, 31(6): 1–12.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, *et al*. 2011. FGF23 induces left ventricular hypertrophy. *J Clin Invest*, 121(11): 4393–4408.

UNIVERSITAS GADJAH MADA
FIBROBLAST GROWTH FACTOR 23 SEBAGAI PENANDA KEJADIAN HIPERTROFI DAN DISFUNGSI VENTRIKEL KIRI PADA
PASIEN ANAK DENGAN CHRONIC KIDNEY DISEASE
YULI PRIHASTUTI, Prof.dr.Madarina Julia, MPH, Sp.A(K).; dr. Noormanto, Sp.A (K)
Universitas Gadjah Mada, 2019 | Diunduh dari http://etd.repository.ugm.ac.id/

Ferris ME, Gipson DS, Kimmel PL, Eggers PW. 2006. Trends in treatment and outcomes of survival of adolescents initiating end-stage renal disease care in the United States of America. *Pediatr Nephrol*, 21(7): 1020–1026.

Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, *et al*. 2017. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*, 140(3): e20171904.

Geary DF, Schaefer F. 2008. Comprehensive pediatric nephrology. 1st edition. Philadelphia.

Gruppen MP, Groothoff JW, Prins M, Van der Wouw P, Offringa M, Bos WJ, *et al*. 2003. Cardiac disease in young adult patients with end-stage renal disease since childhood: A Dutch cohort study. *Kidney Int*, 63(3): 1058–1065.

Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, *et al*. 2009. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. *Circulation*, 119(19): 2545–2552.

Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, *et al*. 2008. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. *N Engl J Med*, 359(6): 584–592.

Harambat J, Van Stralen KJ, Kim JJ, Tizard EJ. 2012. Epidemiology of chronic kidney disease in children. *Pediatr Nephrol*, 27(3): 363–373.

Haring R, Enserro D, Xanthakis V, Mitchell GF, Benjamin EJ, Hamburg NM, *et al*. 2016. Plasma fibroblast growth factor 23: clinical correlates and association with cardiovascular disease and mortality in the Framingham Heart Study. *J Am Heart Assoc*, 5(7).

Hosseini MM, Sadat ZN, Kazempour M, Sadeghi R, Dadras SM, Tabiban S. 2017. Assessment of fibroblast growth factor 23 (FGF23) as risk factor for diastolic dysfunction in hemodialysis patients. *J Nephrol Ren Dis*, 01(02).

Hsu HJ, Wu MS. 2009. Fibroblast growth factor 23: A possible cause of left ventricular hypertrophy in hemodialysis patients. *Am J Med Sci*, 337(2): 116–122.

Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, *et al*. 2011. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. *Kidney Int*, 79(12): 1370–1378.

Karbasi-Afshar R, Saburi A, Taheri S. 2014. Pediatric patients with renal disease and cardiovascular complications: A literature review. *ARYA Atheroscler*, 10(2): 118–128.

KDIGO. 2017. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney Inter Suppl*, 7(1): 1–60.

Leifheit-Nestler M, Siemer RG, Flasbart K, Richter B, Kirchhoff F, Ziegler WH,

UNIVERSITAS
GADJAH MADA
FIBROBLAST GROWTH FACTOR 23 SEBAGAI PENANDA KEJADIAN HIPERTROFI DAN DISFUNGSI VENTRIKEL KIRI PADA
PASIEN ANAK DENGAN CHRONIC KIDNEY DISEASE
YULI PRIHASTUTI, Prof.dr.Madarina Julia, MPH, Sp.A(K).; dr. Noormanto, Sp.A (K)
Universitas Gadjah Mada, 2019 | Diunduh dari http://etd.repository.ugm.ac.id/

et al. 2016. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. *Nephrol Dial Transplant*, 31(7): 1088–1099.

Liu D, Alvarez-Elías AC, Wile B, Belostotsky V, Filler G. 2017. Deviations from the expected relationship between serum FGF23 and other markers in children with CKD: A cross-sectional study. *BMC Nephrol*, 18(1): 1–10.

Lu X, Hu MC. 2017. Klotho/FGF23 axis in chronic kidney disease and cardiovascular disease. *Kidney Dis*, 3(1): 15–23.

Massengill SF, Ferris M. 2014. Chronic kidney disease in children and adolescents. *Pediatr Rev*, 35(1): 16–29.

Matteucci MC, Wühl E, Picca S, Mastrostefano A, Rinelli G, Romano C, *et al*. 2006. Left ventricular geometry in children with mild to moderate chronic renal insufficiency. *J Am Soc Nephrol*, 17(1): 218–226.

Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, *et al*. 2006. Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. *J Pediatr*, 149(5): 671–675.

Mitsnefes MM. 2012. Cardiovascular disease in children with chronic kidney disease. *J Am Soc of Nephrol*, 23(4): 578–585.

Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, Jüppner H, *et al*. 2018. FGF23 and left ventricular hypertrophy in children with CKD. *Clin J Am Soc Nephrol*, 13(1): 45–52.

Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Strife CF. 2001. Changes in left ventricular mass in children and adolescents during chronic dialysis. *Pediatr Nephrol*, 16(4): 318–323.

Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, Daniels SR. 2003. Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. *Circulation*, 107(6): 864–868.

Mudi A, Ntsinjana H, Dickens C, Levy C, Ballot D. 2017. Cardiac changes and their association with Fetuin-A and fibroblast growth factor 23 in children with chronic kidney disease. Nephron, 136(3): 233–242.

Myung K, P. 2016. Park ' s pediatric cardiology for practitioners. Sixth edition. Philadelphia: Elsevier Saunders.

Nam KH, Kim H, An SY, Lee M, Cha MU, Park JT, *et al.* 2018. Circulating fibroblast growth factor-23 levels are associated with an increased risk of anemia development in patients with nondialysis chronic kidney disease. *Scientific Reports*, 8(1): 7294.

Nielsen TL, Plesner LL, Warming PE, Mortensen OH, Iversen KK, Heaf JG. 2019. FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction. *Nefrologia,* 39(3): 258–268.

UNIVERSITAS GADJAH MADA
FIBROBLAST GROWTH FACTOR 23 SEBAGAI PENANDA KEJADIAN HIPERTROFI DAN DISFUNGSI VENTRIKEL KIRI PADA
PASIEN ANAK DENGAN CHRONIC KIDNEY DISEASE
YULI PRIHASTUTI, Prof.dr.Madarina Julia, MPH, Sp.A(K).; dr. Noormanto, Sp.A (K)
Universitas Gadjah Mada, 2019 | Diunduh dari http://etd.repository.ugm.ac.id/

Pardede S, Chunnaedy S. 2009. Penyakit ginjal kronik. *Sari Pediatri*, 11(3): 1035–1040.

Patel HP. 2010. Early origins of cardiovascular disease in pediatric chronic kidney disease early origins of CVD in pediatric CKD. *Renal Failure*, 32: 1–9.

Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. 2009. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. *Bone*, 45(6): 1161–8.

Pirojsakul, Kwanchai, Mathews, Nisha, Seikaly M. 2015. Chronic kidney disease in children: recent update. *TOUNJ*, 29(Suppl 3: M5): 117–123.

Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, *et al*. 2014. Disordered FGF23 and mineral metabolism in children with CKD. *Clin J Am Soc Nephrol*, 9(2): 344–353.

Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, *et al*. 2016. Fibroblast growth factor 23 and risk of CKD progression in children. *Clin J Am Soc Nephrol*, 11(11): 1989–1998.

Querfeld U, Mitsnefes M. 2008. Cardiovascular disease in pediatric chronic kidney disease. *Comprehensive Pediatr Nephrol*,793–810.

Razzaque S. 2009. The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis. *Nat rev endocrinol*, 5(11): 611–619.

Sinha MD, Turner C, Booth CJ, Waller S, Rasmussen P, Goldsmith DJA, *et al*. 2015. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease. *Pediatr Nephrol*, 30(10): 1843–1852.

Taşdemir M, Eroğlu AG, Canpolat N, Konukoğlu D, Ağbaş A, Sevim MD, *et al*. 2016. Cardiovascular alterations do exist in children with stage-2 chronic kidney disease. *Clin Exp Nephrol*, 20(6): 926–933.

Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, *et al*. 2013. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. *Am J Physiol Endocrinol Metab*, 304(8): E863–E873.

Ulinski T, Genty J, Viau C, Tillous-Borde I, Deschênes G. 2006. Reduction of left ventricular hypertrophy in children undergoing hemodialysis. *Pediatr nephrol,* 21: 1171–1178.

Wang X, Liu J, Drummond CA, Shapiro JI. 2017. Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy. *Expert Opin Ther Targets*, 21(5): 531–541.

Wang X, Shapiro JI. 2019. Evolving concepts in the pathogenesis of uraemic cardiomyopathy. *Nat Rev Nephrol*, 15(3): 159–175.

UNIVERSITAS
GADJAH MADA
FIBROBLAST GROWTH FACTOR 23 SEBAGAI PENANDA KEJADIAN HIPERTROFI DAN DISFUNGSI VENTRIKEL KIRI PADA
PASIEN ANAK DENGAN CHRONIC KIDNEY DISEASE
YULI PRIHASTUTI, Prof.dr.Madarina Julia, MPH, Sp.A(K).; dr. Noormanto, Sp.A (K)
Universitas Gadjah Mada, 2019 | Diunduh dari http://etd.repository.ugm.ac.id/

Warady BA, Ho M. 2003. Morbidity and mortality in children with anemia at initiation of dialysis. *Pediatr Nephrol*, 18(10): 1055–1062.

Weaver DJ, Kimball TR, Koury PR, Mitsnefes MM. 2009. Cardiac output and associated left ventricular hypertrophy in pediatric chronic kidney disease. *Pediatr Nephrol*, 24(3): 565–570.

Weaver DJ, Mitsnefes M. 2018. Cardiovascular disease in children and adolescents with chronic kidney disease. *Semin Nephrol*, 38(6): 559–569.

Wesseling K, Bakkaloglu S, Salusky I. 2008. Chronic kidney disease mineral and bone disorder in children. *Pediatr Nephrol*, 23(2): 195–207.

Whyte DA, Fine RN. 2008. Chronic kidney disease in children. *Pediatr Rev*, 29(10): 335–341.

Wilson A, Mitsnefes M. 2009. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. *Am J Kidney Dis*, 54(2): 345–360.